CAMZYOS Drug Patent Profile
✉ Email this page to a colleague
When do Camzyos patents expire, and when can generic versions of Camzyos launch?
Camzyos is a drug marketed by Bristol and is included in one NDA. There are two patents protecting this drug.
This drug has sixty-seven patent family members in thirty-nine countries.
The generic ingredient in CAMZYOS is mavacamten. One supplier is listed for this compound. Additional details are available on the mavacamten profile page.
DrugPatentWatch® Generic Entry Outlook for Camzyos
Camzyos will be eligible for patent challenges on April 28, 2026. This date may extended up to six months if a pediatric exclusivity extension is applied to the drug's patents.
By analyzing the patents and regulatory protections it appears that the earliest date
for generic entry will be April 28, 2029. This may change due to patent challenges or generic licensing.
Indicators of Generic Entry
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for CAMZYOS?
- What are the global sales for CAMZYOS?
- What is Average Wholesale Price for CAMZYOS?
Summary for CAMZYOS
| International Patents: | 67 |
| US Patents: | 2 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 22 |
| Patent Applications: | 16 |
| Drug Prices: | Drug price information for CAMZYOS |
| What excipients (inactive ingredients) are in CAMZYOS? | CAMZYOS excipients list |
| DailyMed Link: | CAMZYOS at DailyMed |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for CAMZYOS
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Pharmacology for CAMZYOS
| Drug Class | Cardiac Myosin Inhibitor |
| Mechanism of Action | Cardiac Myosin Inhibitors |
US Patents and Regulatory Information for CAMZYOS
CAMZYOS is protected by two US patents and three FDA Regulatory Exclusivities.
Based on analysis by DrugPatentWatch, the earliest date for a generic version of CAMZYOS is ⤷ Sign Up.
This potential generic entry date is based on TREATMENT OF ADULTS WITH SYMPTOMATIC NEW YORK HEART ASSOCIATION (NYHA) CLASS II-III OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY (HCM) TO IMPROVE FUNCTIONAL CAPACITY AND SYMPTOMS.
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
Patents protecting CAMZYOS
Pyrimidinedione compounds
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF ADULTS WITH SYMPTOMATIC NEW YORK HEART ASSOCIATION (NYHA) CLASS II-III OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY (HCM) TO IMPROVE FUNCTIONAL CAPACITY AND SYMPTOMS
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
FDA Regulatory Exclusivity protecting CAMZYOS
TREATMENT OF ADULTS WITH SYMPTOMATIC NEW YORK HEART ASSOCIATION (NYHA) CLASS II-III OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY (HCM) TO IMPROVE FUNCTIONAL CAPACITY AND SYMPTOMS
Exclusivity Expiration: ⤷ Sign Up
NEW CHEMICAL ENTITY
Exclusivity Expiration: ⤷ Sign Up
LABELING CHANGES BASED ON RESULTS FROM CLINICAL STUDY MYK-461-017
Exclusivity Expiration: ⤷ Sign Up
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bristol | CAMZYOS | mavacamten | CAPSULE;ORAL | 214998-001 | Apr 28, 2022 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Bristol | CAMZYOS | mavacamten | CAPSULE;ORAL | 214998-004 | Apr 28, 2022 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Bristol | CAMZYOS | mavacamten | CAPSULE;ORAL | 214998-002 | Apr 28, 2022 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | Y | ⤷ Sign Up | ||
| Bristol | CAMZYOS | mavacamten | CAPSULE;ORAL | 214998-001 | Apr 28, 2022 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Bristol | CAMZYOS | mavacamten | CAPSULE;ORAL | 214998-003 | Apr 28, 2022 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | Y | ⤷ Sign Up | ||
| Bristol | CAMZYOS | mavacamten | CAPSULE;ORAL | 214998-004 | Apr 28, 2022 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Bristol | CAMZYOS | mavacamten | CAPSULE;ORAL | 214998-002 | Apr 28, 2022 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
EU/EMA Drug Approvals for CAMZYOS
| Company | Drugname | Inn | Product Number / Indication | Status | Generic | Biosimilar | Orphan | Marketing Authorisation | Marketing Refusal |
|---|---|---|---|---|---|---|---|---|---|
| Bristol-Myers Squibb Pharma EEIG | Camzyos | mavacamten | EMEA/H/C/005457 Treatment of symptomatic obstructive hypertrophic cardiomyopathy. |
Authorised | no | no | no | 2023-06-26 | |
| >Company | >Drugname | >Inn | >Product Number / Indication | >Status | >Generic | >Biosimilar | >Orphan | >Marketing Authorisation | >Marketing Refusal |
International Patents for CAMZYOS
When does loss-of-exclusivity occur for CAMZYOS?
Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:
Australia
Patent: 14281408
Patent: Pyrimidinedione compounds against cardiac conditions
Estimated Expiration: ⤷ Sign Up
Patent: 18264088
Patent: Pyrimidinedione compounds against cardiac conditions
Estimated Expiration: ⤷ Sign Up
Patent: 20204271
Patent: Pyrimidinedione compounds against cardiac conditions
Estimated Expiration: ⤷ Sign Up
Patent: 22202298
Patent: Pyrimidinedione compounds against cardiac conditions
Estimated Expiration: ⤷ Sign Up
Brazil
Patent: 2015031864
Patent: compostos de pirimidinadiona contra as condições cardíacas
Estimated Expiration: ⤷ Sign Up
Canada
Patent: 15967
Patent: COMPOSES DE PYRIMIDINE-DIONE CONTRE LES AFFECTIONS CARDIAQUES (PYRIMIDINEDIONE COMPOUNDS AGAINST CARDIAC CONDITIONS)
Estimated Expiration: ⤷ Sign Up
Chile
Patent: 15003689
Patent: Compuestos derivados de 6-(bencil, heteroaril)aminopirimidina-2,4(1h,3h)-diona y sus sales; composicion farmaceutica que los comprende; y su uso para tratar una cardiomiopatia hipertrofica (hcm) o un trastorno cardiaco que tiene una caracteristica patofisiologica asociada con hcm.
Estimated Expiration: ⤷ Sign Up
China
Patent: 5473576
Patent: Pyrimidinedione compounds against cardiac conditions
Estimated Expiration: ⤷ Sign Up
Patent: 9384729
Patent: 针对心脏病症的嘧啶二酮化合物 (Pyrimidinedione compounds against cardiac conditions)
Estimated Expiration: ⤷ Sign Up
Costa Rica
Patent: 160032
Patent: COMPUESTOS DE PIRIMIDINODIONA CONTRA ESTADOS CARDÍACOS
Estimated Expiration: ⤷ Sign Up
Croatia
Patent: 0200379
Estimated Expiration: ⤷ Sign Up
Cyprus
Patent: 22964
Estimated Expiration: ⤷ Sign Up
Denmark
Patent: 10910
Estimated Expiration: ⤷ Sign Up
Dominican Republic
Patent: 015000300
Patent: COMPUESTOS DE PIRIMIDINODIONA CONTRA ESTADOS CARDÍACOS
Estimated Expiration: ⤷ Sign Up
Eurasian Patent Organization
Patent: 0846
Patent: СОЕДИНЕНИЯ ПИРИМИДИНДИОНА (PYRIMIDINEDIONE COMPOUNDS)
Estimated Expiration: ⤷ Sign Up
Patent: 1690066
Patent: СОЕДИНЕНИЯ ПИРИМИДИНДИОНА
Estimated Expiration: ⤷ Sign Up
Patent: 1891009
Patent: СОЕДИНЕНИЯ ПИРИМИДИНДИОНА
Estimated Expiration: ⤷ Sign Up
European Patent Office
Patent: 10910
Patent: COMPOSÉS PYRIMIDINEDIONE CONTRE LES MALADIES CARDIAQUES (PYRIMIDINEDIONE COMPOUNDS AGAINST CARDIAC CONDITIONS)
Estimated Expiration: ⤷ Sign Up
Patent: 02352
Patent: COMPOSÉ DE PYRIMIDINEDIONE CONTRE LES MALADIES CARDIAQUES (PYRIMIDINEDIONE COMPOUND AGAINST CARDIAC CONDITIONS)
Estimated Expiration: ⤷ Sign Up
Finland
Patent: 0230036
Estimated Expiration: ⤷ Sign Up
France
Patent: C1047
Estimated Expiration: ⤷ Sign Up
Guatemala
Patent: 1500348
Patent: COMPUESTOS DE PIRIMIDINODIONA CONTRA ESTADOS CARDÍACOS
Estimated Expiration: ⤷ Sign Up
Hong Kong
Patent: 23930
Patent: 對抗心臟疾病的嘧啶化合物 (PYRIMIDINEDIONE COMPOUNDS AGAINST CARDIAC CONDITIONS)
Estimated Expiration: ⤷ Sign Up
Hungary
Patent: 47566
Estimated Expiration: ⤷ Sign Up
Patent: 300042
Estimated Expiration: ⤷ Sign Up
Israel
Patent: 3222
Patent: תרכובת פירימידינדיאון נגד הפרעות לבביות (Pyrimidinedione compounds against cardiac conditions)
Estimated Expiration: ⤷ Sign Up
Patent: 5837
Patent: תרכובות פירימידינדיאון נגד הפרעות לבביות (Pyrimidinedione compounds against cardiac conditions)
Estimated Expiration: ⤷ Sign Up
Patent: 5971
Patent: תרכובות פירימידינדיאון נגד הפרעות לבביות (Pyrimidinedione compounds against cardiac conditions)
Estimated Expiration: ⤷ Sign Up
Patent: 2299
Patent: תרכובות פירימידינדיאון נגד הפרעות לבביות (Pyrimidinedione compounds against cardiac conditions)
Estimated Expiration: ⤷ Sign Up
Japan
Patent: 03213
Estimated Expiration: ⤷ Sign Up
Patent: 80734
Estimated Expiration: ⤷ Sign Up
Patent: 76556
Estimated Expiration: ⤷ Sign Up
Patent: 16522263
Patent: 心臓状態に対するピリミジンジオン化合物
Estimated Expiration: ⤷ Sign Up
Patent: 20019809
Patent: 心臓状態に対するピリミジンジオン化合物 (PYRIMIDINEDIONE COMPOUNDS FOR CARDIAC CONDITIONS)
Estimated Expiration: ⤷ Sign Up
Patent: 22036966
Patent: 心臓状態に対するピリミジンジオン化合物
Estimated Expiration: ⤷ Sign Up
Patent: 24010108
Patent: 心臓状態に対するピリミジンジオン化合物 (PYRIMIDINEDIONE COMPOUNDS AGAINST CARDIAC CONDITIONS)
Estimated Expiration: ⤷ Sign Up
Lithuania
Patent: 10910
Estimated Expiration: ⤷ Sign Up
Malaysia
Patent: 0860
Patent: PYRIMIDINEDIONE COMPOUNDS AGAINST CARDIAC CONDITIONS
Estimated Expiration: ⤷ Sign Up
Mexico
Patent: 15017865
Patent: COMPUESTOS DE PIRIMIDINODIONA CONTRA ESTADOS CARDIACOS. (PYRIMIDINEDIONE COMPOUNDS AGAINST CARDIAC CONDITIONS.)
Estimated Expiration: ⤷ Sign Up
Patent: 21005326
Patent: COMPUESTOS DE PIRIMIDINODIONA CONTRA ESTADOS CARDIACOS. (PYRIMIDINEDIONE COMPOUNDS AGAINST CARDIAC CONDITIONS.)
Estimated Expiration: ⤷ Sign Up
Patent: 22014414
Patent: COMPUESTOS DE PIRIMIDINODIONA CONTRA ESTADOS CARDIACOS. (PYRIMIDINEDIONE COMPOUNDS AGAINST CARDIAC CONDITIONS.)
Estimated Expiration: ⤷ Sign Up
Morocco
Patent: 789
Patent: Composés de pyrimidine-dione contre les affections cardiaques
Estimated Expiration: ⤷ Sign Up
Netherlands
Patent: 1253
Estimated Expiration: ⤷ Sign Up
New Zealand
Patent: 5456
Patent: Pyrimidinedione compounds against cardiac conditions
Estimated Expiration: ⤷ Sign Up
Norway
Patent: 23043
Estimated Expiration: ⤷ Sign Up
Peru
Patent: 160208
Patent: COMPUESTOS DE PIRIMIDINODIONA CONTRA ESTADOS CARDIACOS
Estimated Expiration: ⤷ Sign Up
Philippines
Patent: 015502794
Patent: PYRIMIDINEDIONE COMPOUNDS AGAINST CARDIAC CONDITIONS
Estimated Expiration: ⤷ Sign Up
Poland
Patent: 10910
Estimated Expiration: ⤷ Sign Up
Portugal
Patent: 10910
Estimated Expiration: ⤷ Sign Up
Serbia
Patent: 906
Patent: PIRIMIDINDIONSKA JEDINJENJA PROTIV SRČANIH STANJA (PYRIMIDINEDIONE COMPOUNDS AGAINST CARDIAC CONDITIONS)
Estimated Expiration: ⤷ Sign Up
Singapore
Patent: 201803459T
Patent: PYRIMIDINEDIONE COMPOUNDS AGAINST CARDIAC CONDITIONS
Estimated Expiration: ⤷ Sign Up
Patent: 201510163T
Patent: PYRIMIDINEDIONE COMPOUNDS AGAINST CARDIAC CONDITIONS
Estimated Expiration: ⤷ Sign Up
Slovenia
Patent: 10910
Estimated Expiration: ⤷ Sign Up
South Africa
Patent: 1508959
Patent: PYRIMIDINEDIONE COMPOUNDS AGAINTS CARDIAC CONDITIONS
Estimated Expiration: ⤷ Sign Up
South Korea
Patent: 2304121
Estimated Expiration: ⤷ Sign Up
Patent: 2359158
Estimated Expiration: ⤷ Sign Up
Patent: 160026997
Patent: 심장 상태에 대한 피리미딘디온 화합물 (PYRIMIDINEDIONE COMPOUNDS AGAINST CARDIAC CONDITIONS)
Estimated Expiration: ⤷ Sign Up
Patent: 210118470
Patent: 심장 상태에 대한 피리미딘디온 화합물 (PYRIMIDINEDIONE COMPOUNDS AGAINST CARDIAC CONDITIONS)
Estimated Expiration: ⤷ Sign Up
Patent: 220020410
Patent: 심장 상태에 대한 피리미딘디온 화합물 (PYRIMIDINEDIONE COMPOUNDS AGAINST CARDIAC CONDITIONS)
Estimated Expiration: ⤷ Sign Up
Patent: 230144117
Patent: 심장 상태에 대한 피리미딘디온 화합물 (PYRIMIDINEDIONE COMPOUNDS AGAINST CARDIAC CONDITIONS)
Estimated Expiration: ⤷ Sign Up
Spain
Patent: 73250
Estimated Expiration: ⤷ Sign Up
Tunisia
Patent: 15000553
Patent: PYRIMIDINEDIONE COMPOUNDS AGAINST CARDIAC CONDITIONS
Estimated Expiration: ⤷ Sign Up
Ukraine
Patent: 7929
Patent: СПОЛУКИ ПІРИМІДИНДІОНУ, СПРЯМОВАНІ ПРОТИ СТАНІВ СЕРЦЕВО-СУДИННОЇ СИСТЕМИ (PYRIMIDINEDIONE COMPOUNDS AGAINST CARDIAC CONDITIONS)
Estimated Expiration: ⤷ Sign Up
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
See the table below for additional patents covering CAMZYOS around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| South Korea | 20230144117 | 심장 상태에 대한 피리미딘디온 화합물 (PYRIMIDINEDIONE COMPOUNDS AGAINST CARDIAC CONDITIONS) | ⤷ Sign Up |
| France | 23C1047 | ⤷ Sign Up | |
| Israel | 275837 | תרכובות פירימידינדיאון נגד הפרעות לבביות (Pyrimidinedione compounds against cardiac conditions) | ⤷ Sign Up |
| Lithuania | 3010910 | ⤷ Sign Up | |
| Israel | 310829 | תרכובות פירימידינדיאון נגד הפרעות לבביות (Pyrimidinedione compounds against cardiac conditions) | ⤷ Sign Up |
| Japan | 2022036966 | 心臓状態に対するピリミジンジオン化合物 | ⤷ Sign Up |
| Brazil | 112015031864 | compostos de pirimidinadiona contra as condições cardíacas | ⤷ Sign Up |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for CAMZYOS
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 3010910 | 39/2023 | Austria | ⤷ Sign Up | PRODUCT NAME: MAVACAMTEN ODER EIN PHARMAZEUTISCH VERTRAEGLICHES SALZ DAVON; REGISTRATION NO/DATE: EU/1/23/1716 (MITTTEILUNG) 20230627 |
| 3010910 | PA2023535 | Lithuania | ⤷ Sign Up | PRODUCT NAME: MAVAKAMTENAS ARBA FARMACINIU POZIURIU PRIIMTINA JO DRUSKA; REGISTRATION NO/DATE: EU/1/23/1716 20230626 |
| 3010910 | LUC00324 | Luxembourg | ⤷ Sign Up | PRODUCT NAME: MAVACAMTEN OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; AUTHORISATION NUMBER AND DATE: EU/1/23/1716 20230627 |
| 3010910 | 122023000063 | Germany | ⤷ Sign Up | PRODUCT NAME: MAVACAMTEN ODER EIN PHARMAZEUTISCH UNBEDENKLICHES SALZ DAVON; REGISTRATION NO/DATE: EU/1/23/1716 20230626 |
| 3010910 | 301253 | Netherlands | ⤷ Sign Up | PRODUCT NAME: MAVACAMTEN OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN; REGISTRATION NO/DATE: EU/1/23/1716 20230627 |
| 3010910 | C03010910/01 | Switzerland | ⤷ Sign Up | PRODUCT NAME: MAVACAMTENUM; REGISTRATION NO/DATE: SWISSMEDIC-ZULASSUNG 68477 25.04.2023 |
| 3010910 | 2023C/546 | Belgium | ⤷ Sign Up | PRODUCT NAME: MAVACAMTEN OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI; AUTHORISATION NUMBER AND DATE: EU/1/23/1716 20230627 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
